To that end, a selective inhibitor of the TGF-β receptor in combination with sorafenib prolonged the overall survival of HCC patients [59], while inhibition of downstream kinases of TGF-β in combination with chemotherapy improved the overall survival of PDAC patients [60,61,62]. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.